Sprint Bioscience AB (publ)
STO: SPRINT.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Johan Emilsson
- Employees
- 38
- Headquarters
- Huddinge, Sweden
- IPO year
- 2014
- Market cap
- SEK 421.0M
- Website
- https://www.sprintbioscience.com
Loading SPRINT…
Loading profile data…Frequently asked questions about SPRINT
What does Sprint Bioscience AB (publ) (SPRINT.ST) do?
Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of produc...
Where does SPRINT.ST trade?
Sprint Bioscience AB (publ) (SPRINT.ST) trades on the Stockholm Stock Exchange.
What sector is SPRINT.ST in?
Sprint Bioscience AB (publ) (SPRINT.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Sprint Bioscience AB (publ)?
Johan Emilsson is the chief executive officer of Sprint Bioscience AB (publ) (SPRINT.ST).
Where is Sprint Bioscience AB (publ) headquartered?
Sprint Bioscience AB (publ) is headquartered in Sweden.
Does SPRINT.ST pay a dividend?
Sprint Bioscience AB (publ) (SPRINT.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SPRINT.ST go public?
Sprint Bioscience AB (publ) (SPRINT.ST) completed its initial public offering in 2014.